Information Provided By:
Fly News Breaks for December 27, 2019
Dec 27, 2019 | 11:03 EDT
Oppenheimer analyst Hartaj Singh called United Therapeutics "cheap, unloved and misunderstood," contending that his above-consensus 2020 and beyond sales and earnings estimates "point to a significant disconnect from consensus" if the sales trajectory on the company's core treprostinil franchise is steady, as he assumes. The analyst, who believes investors underestimate the potential sales and earnings leverage from Orenitram and have paid little attention to the upcoming "raft of Phase 3 pipeline catalysts" at United Therapeutics, keeps an Outperform rating and $155 price target on the stock.
News For UTHR From the Last 2 Days
There are no results for your query UTHR